Association of the bleeding time test with aspects of traumatic brain injury in patients with alcohol use disorder.

Alcohol use disorder Hemostasis IVY bleeding time test Injury severity Outcome Platelets Traumatic brain injury

Journal

Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000

Informations de publication

Date de publication:
07 2020
Historique:
received: 29 01 2019
accepted: 29 03 2020
pubmed: 20 5 2020
medline: 7 1 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

Traumatic brain injury (TBI) and alcohol use disorder (AUD) can occur concomitantly and be associated with coagulopathy that influences TBI outcome. The use of bleeding time tests in TBI management is controversial. We hypothesized that in TBI patients with AUD, a prolonged bleeding time is associated with more severe injury and poor outcome. Moderate and severe TBI patients with evidence of AUD were examined with bleeding time according to IVY bleeding time on admission during neurointensive care. Baseline clinical and radiological characteristics were recorded. A standardized IVY bleeding time test was determined by staff trained in the procedure. Bleeding time test results were divided into normal (≤ 600 s), prolonged (> 600 s), and markedly prolonged (≥ 900 s). Normal platelet count (PLT) was defined as > 150,000/μL. This cohort was compared with another group of TBI patients without evidence of AUD. Fifty-two patients with TBI and AUD were identified, and 121 TBI patients without any history of AUD were used as controls. PLT was low in 44.2% and bleeding time was prolonged in 69.2% of patients. Bleeding time values negatively correlated with PLT (p < 0.05). TBI patients with markedly prolonged values (≥ 900 s) had significantly increased hematoma size, and more frequently required intracranial pressure measurement and mechanical ventilation compared with those with bleeding times < 900 s (p < 0.05). Most patients (88%) with low platelet count had prolonged bleeding time. No difference in 6-month outcome between the bleeding time groups was observed (p > 0.05). Subjects with TBI and no evidence for AUD had lower bleeding time values and higher platelet count compared with those with TBI and history of AUD (p < 0.05). Although differences in the bleeding time values between TBI cohorts exist and prolonged values may be seen even in patients with normal platelet count, the bleeding test is a marker of primary hemostasis and platelet function with low specificity. However, it may provide an additional assessment in the interpretation of the overall status of TBI patients with AUD. Therefore, the bleeding time test should only be used in combination with the patient's bleeding history and careful assessment of other hematologic parameters.

Sections du résumé

BACKGROUND-AIM
Traumatic brain injury (TBI) and alcohol use disorder (AUD) can occur concomitantly and be associated with coagulopathy that influences TBI outcome. The use of bleeding time tests in TBI management is controversial. We hypothesized that in TBI patients with AUD, a prolonged bleeding time is associated with more severe injury and poor outcome.
MATERIAL AND METHODS
Moderate and severe TBI patients with evidence of AUD were examined with bleeding time according to IVY bleeding time on admission during neurointensive care. Baseline clinical and radiological characteristics were recorded. A standardized IVY bleeding time test was determined by staff trained in the procedure. Bleeding time test results were divided into normal (≤ 600 s), prolonged (> 600 s), and markedly prolonged (≥ 900 s). Normal platelet count (PLT) was defined as > 150,000/μL. This cohort was compared with another group of TBI patients without evidence of AUD.
RESULTS
Fifty-two patients with TBI and AUD were identified, and 121 TBI patients without any history of AUD were used as controls. PLT was low in 44.2% and bleeding time was prolonged in 69.2% of patients. Bleeding time values negatively correlated with PLT (p < 0.05). TBI patients with markedly prolonged values (≥ 900 s) had significantly increased hematoma size, and more frequently required intracranial pressure measurement and mechanical ventilation compared with those with bleeding times < 900 s (p < 0.05). Most patients (88%) with low platelet count had prolonged bleeding time. No difference in 6-month outcome between the bleeding time groups was observed (p > 0.05). Subjects with TBI and no evidence for AUD had lower bleeding time values and higher platelet count compared with those with TBI and history of AUD (p < 0.05).
CONCLUSIONS
Although differences in the bleeding time values between TBI cohorts exist and prolonged values may be seen even in patients with normal platelet count, the bleeding test is a marker of primary hemostasis and platelet function with low specificity. However, it may provide an additional assessment in the interpretation of the overall status of TBI patients with AUD. Therefore, the bleeding time test should only be used in combination with the patient's bleeding history and careful assessment of other hematologic parameters.

Identifiants

pubmed: 32424564
doi: 10.1007/s00701-020-04373-y
pii: 10.1007/s00701-020-04373-y
pmc: PMC7232602
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1597-1606

Références

Acta Neurochir (Wien). 2018 Feb;160(2):229-237
pubmed: 29234973
Arch Surg. 1998 Feb;133(2):134-9
pubmed: 9484723
J Neurotrauma. 2011 Feb;28(2):203-15
pubmed: 21294647
J Trauma Acute Care Surg. 2014 Dec;77(6):865-71; discussion 871-2
pubmed: 25099451
Acta Neurochir (Wien). 2008 Feb;150(2):165-75; discussion 175
pubmed: 18166989
Lakartidningen. 2001 Sep 12;98(37):3922-4
pubmed: 11586831
Lancet Neurol. 2017 Aug;16(8):630-647
pubmed: 28721927
Crit Care Nurs Clin North Am. 2013 Dec;25(4):427-34, v
pubmed: 24267279
Gastrointest Endosc. 1994 Sep-Oct;40(5):599-602
pubmed: 7988826
Med J Aust. 2013 Mar 4;198(4):198-9
pubmed: 23451962
J Neurotrauma. 2007 Nov;24(11):1699-706
pubmed: 18001200
Clin Lab Haematol. 2000 Oct;22 Suppl 1:9-11; discussion 30-2
pubmed: 11251652
Br J Haematol. 1981 May;48(1):31-7
pubmed: 7248189
J Trauma. 2009 Jan;66(1):55-61; discussion 61-2
pubmed: 19131806
J Neurosurg. 2015 Jan;122(1):211-8
pubmed: 25361494
Front Neurol. 2017 Oct 17;8:540
pubmed: 29089921
Neurosurgery. 1992 Feb;30(2):160-5
pubmed: 1545882
Am J Clin Pathol. 1989 Jan;91(1):45-51
pubmed: 2910014
Lancet. 1974 Jul 13;2(7872):81-4
pubmed: 4136544
ARYA Atheroscler. 2014 Jul;10(4):199-202
pubmed: 25258635
Blood Transfus. 2011 Jan;9(1):19-40
pubmed: 21235852
Thromb Res. 1995 Apr 15;78(2):107-15
pubmed: 7482428
Ups J Med Sci. 2017 Aug;122(3):177-184
pubmed: 28463046
J Trauma. 2008 Oct;65(4):748-54
pubmed: 18849786
Haemostasis. 1984;14(2):223-8
pubmed: 6735279
Neurosurg Clin N Am. 2016 Oct;27(4):409-39
pubmed: 27637393
Lakartidningen. 2013 Apr 3-16;110(27-28):1276-7
pubmed: 23951880
J Am Coll Surg. 2010 Jun;210(6):997-1007
pubmed: 20510810
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
J Thromb Haemost. 2018 Apr;16(4):652-662
pubmed: 29363269
Neurocrit Care. 2004;1(4):479-88
pubmed: 16174954
Blood. 1994 Nov 15;84(10):3363-70
pubmed: 7949090
Blood Rev. 2005 Mar;19(2):111-23
pubmed: 15603914
Circulation. 2001 Sep 18;104(12):1367-73
pubmed: 11560851
Semin Thromb Hemost. 1990 Jan;16(1):1-20
pubmed: 2406907
Crit Care Med. 2002 Sep;30(9):2129-34
pubmed: 12352052
J Neurosurg. 2002 Jan;96(1):109-16
pubmed: 11794591
Neurosurgery. 1993 Jan;32(1):25-30; discussion 30-1
pubmed: 8421553
Am J Clin Pathol. 2005 Jun;123 Suppl:S96-105
pubmed: 16100871
J Oral Maxillofac Surg. 1996 Sep;54(9):1119-20
pubmed: 8811825
Am J Clin Pathol. 1989 Sep;92(3):315-20
pubmed: 2672778
Blood. 1991 Jun 15;77(12):2547-52
pubmed: 2043759
Alcohol Health Res World. 1997;21(1):42-52
pubmed: 15706762
J Clin Pathol. 1988 Dec;41(12):1322-30
pubmed: 3225335
Neurocrit Care. 2010 Apr;12(2):211-9
pubmed: 19806475
Semin Thromb Hemost. 2008 Feb;34(1):97-103
pubmed: 18393146
Crit Care. 2019 Feb 22;23(1):62
pubmed: 30795779
J Neurotrauma. 2012 Nov 20;29(17):2597-605
pubmed: 23020190
Neurosurgery. 2012 Jun;70(6):1334-45
pubmed: 22307074
J Neurotrauma. 1995 Oct;12(5):883-90
pubmed: 8594215
Semin Hematol. 1980 Apr;17(2):137-47
pubmed: 6990498
N Engl J Med. 1991 Jan 3;324(1):27-39
pubmed: 1984161
Crit Care Clin. 2004 Jan;20(1):101-18
pubmed: 14979332

Auteurs

P P Tsitsopoulos (PP)

Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden. ptsitsopoulos@auth.gr.

N Marklund (N)

Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
Department of Clinical Sciences Lund, Neurosurgery, Skåne University Hospital, Lund University, Lund, Sweden.

E Rostami (E)

Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

P Enblad (P)

Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

L Hillered (L)

Department of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH